KIT Amplification

CI-VAR-00000218Explore in graph →CIViC 586

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Melanoma1
KIT Amplification	Nilotinib	Predictive	B	Supports Resistance	3	submitted	EID5907 This phase II trial showed that nilotinib demonstrates response in a subset of melanoma patients (acral and mucosal subtypes) with KIT mutations. Median duration of response was 34 weeks. Of the 42 pa… (full text at CIViC) PMID 26424760 · Lee et al., 2015 · Open in CIViC	civic
Mucosal Melanoma1
KIT Amplification	Imatinib	Predictive	B	Supports Resistance	3	accepted	EID1466 Phase 2 trial in metastatic mucosal, acral or chronically sun-damaged melanoma. Twenty-five patients were enrolled (24 evaluable). Eight patients (33%) had tumors with KIT mutations, 11 (46%) with KIT… (full text at CIViC) PMID 23775962 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.